<?xml version="1.0" encoding="UTF-8"?>
<p>After unanticipated harm occurred from in utero exposure to thalidomide and diethylstilbestrol in the 1960s and 1970s, the United States Food and Drug Administration (FDA) enacted policies to protect women research participants of reproductive age from teratogenic exposure [
 <xref rid="pmed.1002882.ref015" ref-type="bibr">15</xref>]. An unintended consequence has been the uniform exclusion of pregnant women from Phase III trials of TB therapies, even for MDR and extremely drug-resistant (XDR) TB [
 <xref rid="pmed.1002882.ref007" ref-type="bibr">7</xref>,
 <xref rid="pmed.1002882.ref008" ref-type="bibr">8</xref>]. Exclusion has been based on concerns of legal liability as well as new or increased frequency/severity of adverse events and potential unpredictability of such events in pregnancy or the postpartum period. Ethical complexities and insufficient market interests for developing pediatric formulations and concerns of potential DDIs among antiretrovirals and TB therapies are among the factors preventing adequate trial data from being collected from child and HIVâ€“TB-coinfected populations, particularly those with advanced immunosuppression.
</p>
